Non‐small cell lung cancer in China
P Chen, Y Liu, Y Wen, C Zhou - Cancer Communications, 2022 - Wiley Online Library
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …
Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review
Importance Personalized medicine based on tumor profiling and identification of actionable
genomic alterations is pivotal in cancer management. Although tissue biopsy is still …
genomic alterations is pivotal in cancer management. Although tissue biopsy is still …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
[HTML][HTML] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost,
morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is …
morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is …
A clinician's handbook for using ctDNA throughout the patient journey
SO Hasenleithner, MR Speicher - Molecular cancer, 2022 - Springer
Background The promise of precision cancer medicine presently centers around the
genomic sequence of a patient's tumor being translated into timely, actionable information to …
genomic sequence of a patient's tumor being translated into timely, actionable information to …
Liquid biopsy in cancer current: status, challenges and future prospects
L Ma, H Guo, Y Zhao, Z Liu, C Wang, J Bu… - … and Targeted Therapy, 2024 - nature.com
Cancer has a high mortality rate across the globe, and tissue biopsy remains the gold
standard for tumor diagnosis due to its high level of laboratory standardization, good …
standard for tumor diagnosis due to its high level of laboratory standardization, good …
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …
revolutionised the management of patients with solid tumours. Recent advances in the …
[HTML][HTML] Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study
Background Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated
into the clinical management of patients with advanced cancer. Beyond tumor profiling …
into the clinical management of patients with advanced cancer. Beyond tumor profiling …
[HTML][HTML] Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …
and provide unique insights into the evolving molecular landscape of cancers under the …